Benzinga · Mar 3, 2026
SO
NASDAQ · SOPH
SOPHiA GENETICS S.A.
Healthcare · Medical - Healthcare Information Services
$7.22
Down-$0.19 (-2.56%)
Updated Oct 13, 2026, 11:33 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 321.51M
- P/E ratio
- -4.39
- Dividend yield
- 0.00%
- 52-week range
- $4.28 – $8.98
- Volume
- 478.89K
- Avg. volume
- 114.15K
Price performance · SOPH
SOPH price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
SOPH closed at $7.22 after 21 trading sessions, down 8.14% for the selected period.
- Last close
- $7.22
- Period change
- -8.14%
- Period low
- $7.15
- Period high
- $8.53
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $7.44 | $7.69 | $7.01 | $7.22 | 478.89K |
| Oct 9, 2026 | $7.32 | $7.4636 | $7.07 | $7.41 | 328.12K |
| Oct 8, 2026 | $7.15 | $7.40 | $6.8405 | $7.30 | 499.92K |
| Oct 7, 2026 | $7.26 | $7.3696 | $7.08 | $7.15 | 432.83K |
| Oct 6, 2026 | $8.40 | $8.564 | $7.335 | $7.38 | 929.1K |
| Oct 5, 2026 | $8.10 | $8.34 | $7.90 | $8.20 | 1.18M |
| Oct 2, 2026 | $8.10 | $8.375 | $7.93 | $8.07 | 748.04K |
| Oct 1, 2026 | $8.50 | $8.50 | $7.91 | $8.03 | 701K |
| Sep 30, 2026 | $8.48 | $8.67 | $8.2824 | $8.38 | 471.24K |
| Sep 29, 2026 | $8.50 | $8.59 | $8.14 | $8.30 | 315.15K |
| Sep 28, 2026 | $8.33 | $8.731 | $8.10 | $8.49 | 547.68K |
| Sep 25, 2026 | $8.35 | $8.51 | $8.235 | $8.34 | 519.73K |
| Sep 24, 2026 | $8.08 | $8.315 | $7.89 | $8.26 | 426.43K |
| Sep 23, 2026 | $8.00 | $8.18 | $7.932 | $8.08 | 563.01K |
| Sep 22, 2026 | $8.25 | $8.51 | $8.04 | $8.07 | 571.53K |
| Sep 21, 2026 | $8.33 | $8.33 | $7.92 | $8.24 | 430.11K |
| Sep 18, 2026 | $8.55 | $8.70 | $8.12 | $8.19 | 965.13K |
| Sep 17, 2026 | $8.10 | $8.60 | $8.06 | $8.53 | 1.21M |
| Sep 16, 2026 | $7.98 | $8.10 | $7.8305 | $7.975 | 1.49M |
| Sep 15, 2026 | $7.85 | $7.98 | $7.76 | $7.96 | 1.86M |
| Sep 14, 2026 | $7.87 | $8.00 | $7.755 | $7.86 | 309.53K |
Latest SOPH news
The latest Smart Investors Daily articles mentioning SOPH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SOPH research
Overview
Company profile and research snapshot.
Company profile
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $5.33
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 15, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 3, 2026
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
ChartMill · Mar 3, 2026
SOPHiA GENETICS SA (NASDAQ:SOPH) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss
SOPHiA GENETICS reports Q4 2025 revenue beat but wider-than-expected loss, highlighting growth in AI-driven genomic analysis as path to profitability continues.
SeekingAlpha · Mar 3, 2026
SOPHiA GENETICS SA 2025 Q4 - Results - Earnings Call Presentation
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
